Login to Your Account

Financings Roundup

SARcode's Work in Dry Eye Attracts $44M Series B Round

By Jennifer Boggs

Monday, July 18, 2011
Late last year, SARcode Bioscience Inc.'s new CEO indicated in a BioWorld interview plans for a Series B round early in 2011 to take its dry eye drug candidate into pivotal testing. (See BioWorld Today, Dec. 29, 2010.)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription